Additionally, studies have shown that combining enzalutamide with the enhancer of zeste homolog 2 (EZH2) inhibitor GSK-126 remodels the tumor immune microenvironment by activating CD8+ T cells and IFN-γ production [122]. Here, CD8A is linked to neoplasm.